Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice
(2010) In Blood 116(12). p.2103-2111- Abstract
- The 8p11 myeloproliferative syndrome (EMS), also referred to as stem cell leukemia/lymphoma, is a chronic myeloproliferative disorder that rapidly progresses into acute leukemia. Molecularly, EMS is characterized by fusion of various partner genes to the FGFR1 gene, resulting in constitutive activation of the tyrosine kinases in FGFR1. To date, no previous study has addressed the functional consequences of ectopic FGFR1 expression in the potentially most relevant cellular context, that of normal primary human hematopoietic cells. Herein, we report that expression of ZMYM2/FGFR1 (previously known as ZNF198/FGFR1) or BCR/FGFR1 in normal human CD34(+) cells from umbilicalcord blood leads to increased cellular proliferation and differentiation... (More)
- The 8p11 myeloproliferative syndrome (EMS), also referred to as stem cell leukemia/lymphoma, is a chronic myeloproliferative disorder that rapidly progresses into acute leukemia. Molecularly, EMS is characterized by fusion of various partner genes to the FGFR1 gene, resulting in constitutive activation of the tyrosine kinases in FGFR1. To date, no previous study has addressed the functional consequences of ectopic FGFR1 expression in the potentially most relevant cellular context, that of normal primary human hematopoietic cells. Herein, we report that expression of ZMYM2/FGFR1 (previously known as ZNF198/FGFR1) or BCR/FGFR1 in normal human CD34(+) cells from umbilicalcord blood leads to increased cellular proliferation and differentiation toward the erythroid lineage in vitro. In immunodeficient mice, expression of ZMYM2/FGFR1 or BCR/FGFR1 in human cells induces several features of human EMS, including expansion of several myeloid cell lineages and accumulation of blasts in bone marrow. Moreover, bone marrow fibrosis together with increased extramedullary hematopoiesis is observed. This study suggests that FGFR1 fusion oncogenes, by themselves, are capable of initiating an EMS-like disorder, and provides the first humanized model of a myeloproliferative disorder transforming into acute leukemia in mice. The established in vivo EMS model should provide a valuable tool for future studies of this disorder. (Blood. 2010;116(12):2103-2111) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1695454
- author
- organization
-
- Division of Clinical Genetics
- Division of Molecular Medicine and Gene Therapy
- Department of Laboratory Medicine
- Tumor microenvironment
- Translational Genomic and Functional Studies of Leukemia (research group)
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 116
- issue
- 12
- pages
- 2103 - 2111
- publisher
- American Society of Hematology
- external identifiers
-
- wos:000282137300018
- pmid:20554971
- scopus:77957196376
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2009-05-217182
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Molecular Medicine and Gene Therapy (013022010), Pathology, (Lund) (013030000), Division of Clinical Genetics (013022003), Department of Laboratory Medicine, Lund (013017000)
- id
- 79d66993-b7b1-4025-aa68-5c958d8b119a (old id 1695454)
- date added to LUP
- 2016-04-01 09:55:07
- date last changed
- 2022-02-02 04:36:30
@article{79d66993-b7b1-4025-aa68-5c958d8b119a, abstract = {{The 8p11 myeloproliferative syndrome (EMS), also referred to as stem cell leukemia/lymphoma, is a chronic myeloproliferative disorder that rapidly progresses into acute leukemia. Molecularly, EMS is characterized by fusion of various partner genes to the FGFR1 gene, resulting in constitutive activation of the tyrosine kinases in FGFR1. To date, no previous study has addressed the functional consequences of ectopic FGFR1 expression in the potentially most relevant cellular context, that of normal primary human hematopoietic cells. Herein, we report that expression of ZMYM2/FGFR1 (previously known as ZNF198/FGFR1) or BCR/FGFR1 in normal human CD34(+) cells from umbilicalcord blood leads to increased cellular proliferation and differentiation toward the erythroid lineage in vitro. In immunodeficient mice, expression of ZMYM2/FGFR1 or BCR/FGFR1 in human cells induces several features of human EMS, including expansion of several myeloid cell lineages and accumulation of blasts in bone marrow. Moreover, bone marrow fibrosis together with increased extramedullary hematopoiesis is observed. This study suggests that FGFR1 fusion oncogenes, by themselves, are capable of initiating an EMS-like disorder, and provides the first humanized model of a myeloproliferative disorder transforming into acute leukemia in mice. The established in vivo EMS model should provide a valuable tool for future studies of this disorder. (Blood. 2010;116(12):2103-2111)}}, author = {{Ågerstam, Helena and Järås, Marcus and Andersson, Anna and Johnels, Petra and Hansen, Nils and Lassen, Carin and Rissler, Marianne and Gisselsson Nord, David and Olofsson, Tor and Richter, Johan and Fan, Xiaolong and Ehinger, Mats and Fioretos, Thoas}}, issn = {{1528-0020}}, language = {{eng}}, number = {{12}}, pages = {{2103--2111}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice}}, url = {{http://dx.doi.org/10.1182/blood-2009-05-217182}}, doi = {{10.1182/blood-2009-05-217182}}, volume = {{116}}, year = {{2010}}, }